CAR therapies

Bio4t2 Begins Dosing Solid Tumor Patients in First-In-Human CAR T-Cell Therapy Trial

2seventy, Bristol Myers Squibb Improving Manufacturing Capacity for Abecma

Arsenal Biosciences Begins Phase I Trial of Cell Therapy in Ovarian Cancer

China's NMPA Accepts New Drug Application for Legend Biotech, Janssen's Carvykti

FDA Clears Iaso Biotherapeutics for US Trials of BCMA-Targeted CAR-T Therapy in Multiple Myeloma

OneChain Immunotherapeutics to Launch CD1a-Targeting CAR T-Cell Therapy Trial in T-Cell Leukemia

Cedars-Sinai Sets Up New Precision Oncology-Focused Lymphoma Program

Gilead Sciences to Acquire Cell Therapy Biotech Tmunity Therapeutics

Invectys, CTMC Begin First-in-Human Trial of HLA-G-Targeting CAR T-Cell Therapy in Solid Tumors

In Brief This Week: Casi Pharmaceuticals, Cofactor Genomics, Point32Health

Immix Biopharma Forms New Subsidiary, In-Licenses Multiple Myeloma CAR T-Cell Therapy

Gilead Sciences, Arcellx Ink Deal to Co-Develop, Commercialize Multiple Myeloma CAR T-Cell Therapy

Daiichi Sankyo Transfers Rights to Market Yescarta in Japan to Gilead Sciences

Coeptis Therapeutics Partners With IQVIA to Advance CAR T-Cell Therapy Into Clinic

Legend Biotech to Launch CAR T-Cell Therapy Trial for Small Cell Lung Cancer, Neuroendocrine Tumors

Ono Pharmaceutical Exercises Option to Jointly Develop CAR T-Cell Therapy With Fate Therapeutics